ChemoCentryx Reports Fourth Quarter 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ChemoCentryx Reports Fourth Quarter 2014 Financial Results and Provides Corporate Update

- - P resentation of CCR2 inhibitor CCX140 Phase II Diabetic Nephropathy results anticipated at upcoming medical meetings --

-- Recruitment projections to complete enrollment in C5aR inhibitor CCX168 CLEAR Phase II ANCA-associated vasculitis clinical trial remain on track --

-- Initial data anticipated from other pipeline programs, including CCX168 in atypical Hemolytic Uremic Syndrome, CCX872 in non-resectable pancreatic cancer, and other pipeline programs --

-- Conference Call Today at 5:00 p.m. Eastern Time --

MOUNTAIN VIEW, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI ), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today reported financial results for the fourth quarter ended December 31, 2014 and provided an update on the Company's corporate and clinical development activities expected in 2015.

"2014 was a year of genuine accomplishments for ChemoCentryx," said Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer. "Particularly important were the successful Phase II clinical results for CCX140 in diabetic nephropathy which we believe provide a clear path forward for Phase III clinical development. Furthermore, our pipeline advanced with the expansion of our CCX168 clinical program into the U.S., and our recently initiated clinical trial in pancreatic cancer with our next-generation CCR2 inhibitor, CCX872. These pipeline advancements enrich the spectrum of partnering efforts in 2015 while increasing also our independent development options."

Recent Developments

CCR2 Program – CCX140 targets the chemokine receptor known as CCR2. The Company successfully completed and reported positive Phase II clinical data with CCX140, the Company's lead CCR2 inhibitor, in patients with diabetic nephropathy. CCX872, a next-generation, orally administered, potent and selective CCR2 inhibitor, has completed Phase I testing in healthy subjects and is now positioned for clinical development in oncology.

  • During the fourth quarter, the Company reported positive data from the CCX140 Phase II trial in patients with diabetic nephropathy, achieving its primary endpoint;
    • Statistically significant improvement in reducing urinary albumin:creatinine ratio (UACR) following oral, daily doses of 5 mg of CCX140 added to a standard of care (SOC) regimen of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor II blocker (ARB) treatment versus SOC on its own.
  • Treatment with CCX140 improved the estimated glomerular filtration rate (eGFR) profile;
    • There was a sustained attenuation in the slope of annual decline in eGFR in the treatment group receiving 5 mg of CCX140 in addition to SOC, which translated into a 44 percent improvement over SOC.
  • CCX140 was safe and well tolerated.
  • A clinical trial of CCX872 in patients with non-resectable pancreatic cancer was initiated earlier this month and is positioned to commence enrollment.

C5aR Program - CCX168 targets the chemoattractant receptor known as C5aR (which binds to the complement fragment C5a). The Company has successfully completed and reported positive clinical data with CCX168 from the first two steps of a three-step Phase II clinical trial, named the CLEAR trial, in patients with anti-neutrophil cytoplasmic antibody, or ANCA, associated vasculitis, or AAV, a disease which can lead to renal and pulmonary failure. C5aR is also believed to play a role in other renal diseases, such as atypical hemolytic uremic syndrome (aHUS) and IgA nephropathy.

  • 12-week data from the Phase II CLEAR trial in patients with AAV, presented at the American College of Rheumatology (ACR) Annual Meeting, in which CCX168 was used in place of high doses of corticosteroids (which are part of the SOC), demonstrated that patients who received CCX168 showed marked improvements in the Birmingham Vasculitis Activity Score (BVAS), an index of ANCA disease activity, in the renal as well as non-renal components of BVAS, and this response was higher than those receiving standard of care.
  • The U.S. Food and Drug Administration (FDA) granted orphan-drug designation for CCX168 for the treatment of aHUS in the fourth quarter.
  • Also during the fourth quarter, the European Commission granted orphan drug designation for CCX168 for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's Granulomatosis). Both conditions are forms of AAV.

Anticipated 2015 Milestones

CCX140, a CCR2 Inhibitor: Prepare for Initiation of a Phase III Clinical Trial

  • Present detailed study results from the previously announced CCX140 Phase II trial in patients with diabetic nephropathy at upcoming medical meetings, with the initial presentation expected in the second quarter of 2015; and
  • Conduct an End-of-Phase 2 meeting with the FDA in the second half of 2015.

CCX872, a Second-Generation CCR2 Inhibitor: Expect to Release Initial Clinical Data

  • Announce initial data from the CCX872 clinical study in patients with non-resectable pancreatic cancer in the second half of 2015.

CCX168, a C5aR Inhibitor: Complete Enrollment of Phase II CLEAR Trial and Initiate Multiple Phase IIa Clinical Trials

  • Complete enrollment in the CCX168 Phase II CLEAR trial in Europe in patients with AAV;
  • Continue enrollment into the CCX168 Phase II CLASSIC trial in North America in patients with AAV;
  • Continue enrollment in the Phase IIa clinical trial of CCX168 in patients with IgA nephropathy;
  • Present data supporting anti-thrombogenic effect of CCX168 in serum from patients with aHUS in the second quarter of 2015; and
  • Initiate proof-of-concept clinical trial with CCX168 in patients with aHUS and report initial results.

Review of Fourth Quarter 2014 Financial Results

Cash, cash equivalents and investments were $114.6 million at December 31, 2014 compared with $149.9 million at December 31, 2013.

There was no revenue recognized for the three months ended December 31, 2014, compared to $0.7 million in the same period in 2013. The decrease in revenues from 2013 to 2014 was primarily due to funding of clinical support from former partner, GlaxoSmithKline (GSK), for CCX168, the Company's C5aR inhibitor, in 2013. ChemoCentryx's product development and commercialization agreement with GSK ended in November 2013, and therefore no revenue was recorded in 2014.

Research and development expenses were $9.1 million for the three months ended December 31, 2014 compared to $7.4 million for the comparable period in 2013. The increase in research and development expenses from 2013 to 2014 was primarily attributed to higher expenses associated with CCX168 due to patient enrollment in the third and final step in the CLEAR Phase II clinical trial in Europe for the treatment of AAV, as well as the expansion of Phase II clinical development for the same in North America in 2014. This increase was partially offset by lower expenses associated with CCX140, the Company's CCR2 inhibitor, due to the completion of the Phase II clinical trial in patients with diabetic nephropathy and CCX872, the Company's second generation CCR2 inhibitor, due to the timing of Phase I related activities.

General and administrative expenses were $3.2 million for the three months ended December 31, 2014, compared to $3.0 million reported for the same in 2013. The increase from 2013 to 2014 was primarily due to higher stock based compensation expense for stock option grants and restricted stock unit awards.

Net loss was $12.2 million for the fourth quarter of 2014 compared to $9.5 million in the same period in 2013.

ChemoCentryx had approximately 43.4 million shares outstanding as of December 31, 2014.

2015 Financial Outlook

The Company started 2015 with approximately $115 million in cash and cash equivalents and is expected to utilize cash in the range of $45 to $49 million for the year.

Conference Call and Webcast

The Company will host a conference call and webcast today, March 12, 2015 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.

To participate by telephone, please dial 877-303-8028 (Domestic) or 760-536-5167 (International). The conference ID number is 91871262.

A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com . The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX140, a CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvements in kidney function in patients with diabetic nephropathy. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. Vercirnon (also known as Traficet-EN or CCX282) is a specific CCR9 inhibitor for the treatment of inflammatory bowel disease. Other clinical programs include CCX872, a next generation CCR2 inhibitor and CCX507, a next generation CCR9 inhibitor, both of which have successfully completed Phase I development and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.

Forward-Looking Statements

ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential" or "continue" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the achievement of anticipated milestones in 2015. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K for the year ended December 31, 2014 which is available from the SEC's website ( www.sec.gov ) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Source: ChemoCentryx, Inc.

CCXI-G

ChemoCentryx, Inc.
 Consolidated Statement of Operations Data 
 (in thousands, except per share data) 
 
   Three Months Ended   Year Ended 
   December 31,   December 31, 
   2014   2013   2014   2013 
         
Consolidated Statement of Operations Data:         
Revenues:         
Collaborative research and development revenue from related party   $ --   $ 725  $ --   $ 6,060
Total revenues   --   725  --   6,060
Operating expenses:         
Research and development   9,121  7,417  33,815  33,541
General and administrative   3,169  2,979  13,584  11,634
Total operating expenses   12,290  10,396  47,399  45,175
Loss from operations   (12,290)  (9,671)  (47,399)  (39,115)
Interest income   103  141  494  501
Interest expense   (3)  (13)  (24)  (59)
Net loss   $ (12,190)  $ (9,543)  $ (46,929)  $ (38,673)
         
Basic and diluted net loss per share   $ (0.28)  $ (0.22)  $ (1.08)  $ (0.95)
         
Shares used to compute basic and diluted net loss per share   43,384  42,877  43,275  40,916
         
         
         
       As of December 31, 
       2014   2013 
       (in thousands) 
Consolidated Balance Sheet Data         
Cash, cash equivalents and investments       $ 114,620  $ 149,874
Working capital       66,139  127,430
Total assets       116,981  152,422
Accumulated deficit       (219,791)  (172,862)
Total stockholders' equity       108,606  145,308

Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer or Markus J. Cappel, Ph.D. Chief Business Officer 650.210.2900 Media: Denise Powell 510.703.9491 Investors: Kimberly Minarovich Burns McClellan 212.213.0006

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 139

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 94

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 108

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 127

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 65

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading

Top 5 Most Recently Viewed Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 420

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
BW LPG Limited Welcomes BW Chinook: A Significant Milestone

Updated Category News Views 180

Significant Acquisition by BW LPG Limited BW LPG Limited has recently taken a remarkable step in enhancing its fleet and operational capabilities. The company announced the acquisition of the vessel BW Chinook, marking an important milestone in its ongoing strategy to strengthen its position in the global LPG market. Details of the Vessel Delivery Following a stock...

Continue Reading
COMAC's Expansion: New Hong Kong Office and Maintenance Deal

Updated Category News Views 175

COMAC's Global Expansion Efforts Chinese planemaker COMAC has taken a significant step in its quest to enter the global passenger jet market by inaugurating its second international office in Hong Kong. This move aligns with their strategy to provide enhanced services and establish a stronger footprint outside mainland China. The opening not only symbolizes growth but...

Continue Reading
Torrid Holdings CEO Lisa Harper Makes Strategic Stock Move

Updated Category News Views 415

Lisa Harper's Recent Sale of Company Shares Lisa Harper, the CEO of Torrid Holdings Inc. (NYSE: CURV), has recently sold shares worth $283,909, according to a filing with the Securities and Exchange Commission. In this transaction, she sold 74,713 shares at a price of $3.80 each. This sale is part of her exercise of the underwriters' option to purchase additional shares...

Continue Reading
Getty Images Plans Q3 2024 Financial Results Release Date

Updated Category News Views 102

Getty Images Announces Q3 2024 Financial Results Date Getty Images Holdings, Inc. (NYSE: GETY), a leader in the global visual content industry, is gearing up to share its financial results for the third quarter of 2024. The results will be unveiled right after market closing on November 7, 2024. This announcement signals an important moment for stakeholders keeping a...

Continue Reading